FDA Approves HER2 Test for Breast Cancer

The Inform Dual ISH test allows for the measurement of the number of copies of the HER2 gene in breast tumor tissue, enabling clinicians to make more informed decisions about whether a patient would be a candidate for Herceptin therapy.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories